Erel Joffe, MD, MSc, Tel Aviv Medical Center, Tel Aviv, Israel, and Memorial Sloan Kettering Cancer Center, New York, NY, discusses the molecular basis of diffuse large B-cell lymphoma (DLBCL), emphasizing the importance of multi-institutional collaborations to improve our understanding of the genetics of this disease. A recent study identified that mutations in CD58 are associated with a poorer prognosis, and mutations in DASP2 are associated with a better response. In addition, this study highlighted the role of epigenetic dysregulation in DLBCL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.